DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



A Study to Explore Pharmacokinetic Interaction Between Rilpivirine and Metformin in Healthy Participants

Information source: Janssen R&D Ireland
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Healthy Participants

Intervention: Metformin (Drug); Rilpivirine (Drug)

Phase: Phase 1

Status: Completed

Sponsored by: Janssen R&D Ireland

Official(s) and/or principal investigator(s):
Janssen R&D Ireland Clinical Trial, Study Director, Affiliation: Janssen R&D Ireland

Summary

The purpose of the study is to evaluate the effect of steady-state (constant concentration of medication in the blood) rilpivirine on pharmacokinetics (how a single dose of metformin is absorbed in the body, distributed within the body, and removed from the body) of a single dose of metformin, over time, in healthy adult participants.

Clinical Details

Official title: A Phase I, Open-Label Study in Healthy Subjects to Explore the Potential for a Pharmacokinetic Interaction Between Steady-State Rilpivirine and a Single Dose Of Metformin

Study design: Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome:

Maximum observed plasma analyte concentration (Cmax) of metformin

Actual sampling time to reach the maximum plasma analyte concentration (tmax) of metformin

Area under curve from time of administration up to the last time point with a measurable plasma analyte concentration after dosing (AUClast) of metformin

AUC extrapolated to infinity of metformin

Apparent terminal elimination rate constant of metformin

Apparent terminal elimination half-life of metformin

Secondary outcome:

Predose plasma analyte concentration (C0h) of rilpivirine

Minimum observed plasma analyte concentration (Cmin) of rilpivirine

Maximum observed plasma analyte concentration (Cmax) of rilpivirine

Actual sampling time to reach the maximum plasma analyte concentration (tmax) of rilpivirine

Observed plasma analyte concentration at the end of the 24-hour dosing interval (C24h)

AUC from time of administration up to 24 hours after administration (AUC24h)

Average steady-state plasma concentration (Css,av)

Fluctuation index (FI)

Number of participants with adverse events as a measure of safety and tolerability

Detailed description: This is a phase I, open-label (all people know the identity of the intervention) and sequential study (study medication is given in a sequence) in healthy participants, to investigate the pharmacokinetic interaction between steady-state rilpivirine and a single dose of metformin. The study consists of 3 phases including, the screening phase (28 days before enrollment), treatment phase (19 days), and the follow-up phase (7 days after the last intake of study medication). All participants will receive study medications in two sessions in a fixed, sequential order as a session 1 (a single dose of metformin on Day 1) followed by washout period (period when no treatment is received) of 4 days and then session 2 (rilpivirine on Day 5 to Day 17 with a single dose of metformin on Day 15). The duration of the study is approximately 54 days. Safety evaluations including adverse events, clinical laboratory tests, electrocardiogram, vital signs, and physical examination (including skin examination) will be monitored throughout the study.

Eligibility

Minimum age: 18 Years. Maximum age: 55 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Participants should be healthy on the basis of physical examination, medical history,

vital signs, electrocardiogram, the results of blood biochemistry and hematology tests and a urinalysis performed at screening

- Participant must have a Body Mass Index of 18. 5 to 30. 0 kg/m2

- Male participants should agree to protocol-defined use of effective contraception and

women must be postmenopausal or surgically sterile

- Female participants must have a negative pregnancy test at screening

- Participants must be non-smoking for at least 3 months prior to screening

Exclusion Criteria:

- A positive Human immunodeficiency virus (HIV)-1 or HIV-2 test and Hepatitis A, B or C

infection at screening

- Currently active clinically significant gastrointestinal, cardiovascular, neurologic,

psychiatric, metabolic, endocrine, renal, hepatic, respiratory, inflammatory or infectious disease with any history of clinically significant skin disease

- Any history of tuberculosis, ocular herpes, or uveitis

- Have previously participated in more than one study with etravirine - TMC120

(dapivirine) and/or rilpivirine

- Participants with abnormal laboratory values at screening

Locations and Contacts

Overland Park, Kansas, United States
Additional Information

Starting date: October 2012
Last updated: March 5, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017